News Release

Enanta Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 28, 2017 at 7:30 AM EST
  • Presentation and Question and Answer Session to be Webcast beginning at 4:00 p.m. PT on January 9, 2018

WATERTOWN, Mass.--(BUSINESS WIRE)--Dec. 28, 2017-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018. The presentation will contain a business overview and an update on Enanta’s research and development programs. A question and answer session with investors will follow the presentation.

A live webcast of the presentation, as well as the question and answer session that follows the presentation, will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcasts will be available following the presentation and will be archived for approximately 60 days.

About Enanta
Enanta Pharmaceuticals has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, paritaprevir and glecaprevir, discovered and developed through Enanta’s collaboration with AbbVie, have now been approved in jurisdictions around the world as part of AbbVie’s direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection, including the marketed regimens MAVYRET™(U.S.) /MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA PAK® (U.S.) (paritaprevir/ritonavir/ombitasvir/dasabuvir). Royalties and milestone payments from the AbbVie collaboration are helping to fund Enanta’s research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.

Source: Enanta Pharmaceuticals, Inc.

Investor Contact:
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com